Current opinion on bevacizumab on endometrial cancer treatment

Bibliography

• Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi33-8
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300
   PubMed Web of Science ®Google Scholar
• Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007;25(20):2983-90
   PubMed Web of Science ®Google Scholar
• Ray M, Fleming G. Management of advanced-stage and recurrent endometrial cancer. Semin Oncol 2009;19:314-20
   Google Scholar
• Zagouri F, Bozas G, Kafantari E, et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet Gynecol Int 2010;2010:749579
   PubMedGoogle Scholar
• Stefansson IM, Salvesen HB, Akslen LA. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res 2006;66(6):3303-9
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3(5):391-400
   PubMed Web of Science ®Google Scholar
• Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007;13(24):7487-95
   PubMed Web of Science ®Google Scholar
• Grothey AE, Ellis LM. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-base therapies. Cancer J 2008;14(3):170-7
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. FDA approval for bevacizumab. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab
   Google Scholar
• Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclincal studies. Cancer Res 2005;65(3):671-80
   PubMed Web of Science ®Google Scholar
• Panares RL, Garcia AA. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 2007;7(4):433-45
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000582/human_med_000663.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Del Campo JM, Prat A, Gil-Moreno A, et al. Update on novel therapeutic agents for cervical cancer. Gyn Oncol 2008;110(3 Suppl 2):S72-6
   PubMed Web of Science ®Google Scholar
• Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997;276(5317):1423-5
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Endo Y, Fujita H, et al. Role of vascular endothelial growth factor c expression in the development of lymph node metastasis in gastric cancer. Clin Can Res 1999;5(7):1823-9
   PubMed Web of Science ®Google Scholar
• Joukov V, Pajusola K, Kaipainem A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15(2):290-8
   PubMed Web of Science ®Google Scholar
• Tsurusaki T, Kanda S, Sakai H, et al. Vascular endothelial growth factor-c expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 1999;80(1-2):309-13
   PubMed Web of Science ®Google Scholar
• Choi WL, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005;18(1):143-52
   PubMed Web of Science ®Google Scholar
• Skobe M, Hawighorsi T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7(2):192-8
   PubMed Web of Science ®Google Scholar
• Mattila MM, Ruohola JK, Karpanen T, et al. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer 2002;98(6):946-51
   PubMed Web of Science ®Google Scholar
• Kitadai Y, Amioka T, Haruma K, et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001;93(5):662-6
   PubMed Web of Science ®Google Scholar
• Dobbs SP, Hewett PW, Johnson IR, et al. Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. Br J Cancer 1997;76(11):1410-15
   PubMed Web of Science ®Google Scholar
• Fujiwaki R, Hata K, Iida K, et al. Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumorcell proliferation, and apoptosis. Anticancer Res 2000;20(2B):1317-22
   PubMed Web of Science ®Google Scholar
• Kodama J, Seki N, Tokumo K, et al. Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer 1999;35(3):485-9
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
   PubMed Web of Science ®Google Scholar
• Rasila KK, Burger RA, Smith H, et al. Angiogenesis in gynecological oncology mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer 2005;15(5):710-26
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-6
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-10
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-64
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Risau W. Mechanisms of angiogenesis. Nature 1997;386(6626):671-4
   PubMed Web of Science ®Google Scholar
• Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest 2000;105(1):17-19
   PubMed Web of Science ®Google Scholar
• Holland CM, Day K, Evans A, et al. Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer 2003;89(5):891-8
   PubMed Web of Science ®Google Scholar
• Hirai M, Nakagawara A, Oosaki T, et al. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 2001;80(2):181-8
   PubMed Web of Science ®Google Scholar
• Kaku T, Kamura T, Kinukawa N, et al. Angiogenesis in endometrial carcinoma. Cancer 1997;80(4):741-7
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-57
   PubMed Web of Science ®Google Scholar
• Hellstrom M, Gerhardt H, Kalen M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001;153(3):543-53
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Eng J Med 2008;358:2335-42
   Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor inpatients with advanced cancer. J Clin Oncol 2001;19:843-50
   PubMed Web of Science ®Google Scholar
• Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288(1):371-8
   PubMed Web of Science ®Google Scholar
• Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779-802
   PubMed Web of Science ®Google Scholar
• Panares RL, Garcia AA. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 2007;7:433-45
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-24
   PubMed Web of Science ®Google Scholar
• Morotti M, Valenzano M, Venturini PL, et al. Bevacizumab in endometrial cancer treatment. Expert Opin Biol Ther 2012;12(5):649-58
   PubMed Web of Science ®Google Scholar
• Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010;23:460-8
   PubMed Web of Science ®Google Scholar
• Tahover E, Uziely B, Salah A, et al. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 2013;30(1):327
   PubMed Web of Science ®Google Scholar
• Lombardi G, Zustovich F, Farina P, et al. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. Anticancer Drugs 2013;24:90-7
   PubMed Web of Science ®Google Scholar
• Liu S, Kurzrock R. Toxicity of targeted therapy: implications for response and impact of genetic polymorphisms. Cancer Treat Rev 2014;40:883-91
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Moisse M, Delmar P, et al. Genetic markers of bevacizumab-induced hypertension. Angiogenesis 2014;17:685-94
   PubMed Web of Science ®Google Scholar
• Schneider BP, Li L, Shen F, et al. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5130 and ECOG-2100. Br J Cancer 2014;111(6):1241-8
   PubMed Web of Science ®Google Scholar
• Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011;10(3):151-6
   PubMed Web of Science ®Google Scholar
• Wu S, Kim C, Baer L, et al. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21:1381-9
   PubMed Web of Science ®Google Scholar
• Syrigos KN, Karapanagiotou E, Boura P, et al. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs 2011;25(3):159-69
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani V, Chuang J, et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol (Madr) 2010;49(3):287-97
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized Phase II and III studies. J Clin Oncol 2011;29(13):1757-64
   PubMed Web of Science ®Google Scholar
• Amit L, Ben-Aharon I, Vidal L, et al. The impact of bevacizumab (Avastin) on survival in metastatic solid tumors - A meta-analysis and systematic review. PLoS One 2013;8(1):e51780
   PubMed Web of Science ®Google Scholar
• Qi WX, Fu S, Zhang Q, et al. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups. Clin Drug Investig 2014;34(10):681-90
   PubMed Web of Science ®Google Scholar
• Zuo PY, Chen XL, Liu YW, et al. Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis. PLoS One 2014;9(7):e102484
   PubMed Web of Science ®Google Scholar
• Elting LS, Chang YC, Parelkar P, et al. Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer 2013;21:3243-54
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Risk factors for GI adverse events in a Phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a gynecologic oncologygroup study. J Clin Oncol 2014;32:1210-17
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Wu S. Treatment related mortality with bevacizumab in cancer patients. A meta-analysis JAMA 2011;305(5):487-94
   PubMed Web of Science ®Google Scholar
• Sivridis E, Giatromanolaki A, Anastasiadis P, et al. Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. J Pathol 2002;196:416-22
   Google Scholar
• Chen CA, Cheng WF, Lee CN, et al. Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival. Gynecol Oncol 2001;80:207-12
   PubMed Web of Science ®Google Scholar
• Davies S, Dai D, Pickett G, et al. Effects of bevacizumab in mouse model of endometrial cancer: defining the molecular basis for resistance. Oncol Rep 2011;25(3):855-62
   PubMed Web of Science ®Google Scholar
• Wright JD, Powell MA, Rader JS, et al. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007;27(5B):3525-8
   PubMed Web of Science ®Google Scholar
• Reinhardt J, Schott S, Mayer C, et al. Long-term remission of an advanced recurrent endometrial cancer in a heavily pre-treated patient using a combined regimen with bevacizumab and metronomic cyclophosphamide. Anticancer Drugs 2011;22:822-4
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study. J Clin Oncol 2011;29:2259-65
   PubMed Web of Science ®Google Scholar
• Moroney J, Fu S, Moulder S, et al. Phase I study of the antiangiogenetic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res 2012;18(20):5796-805
   PubMed Web of Science ®Google Scholar
• Comeford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62(12):3387-94
   PubMed Web of Science ®Google Scholar
• Ellis LH, Kicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008;14(20):6371-5
   PubMed Web of Science ®Google Scholar
• Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92(11):924-30
   PubMed Web of Science ®Google Scholar
• Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005;65(23):10669-73
   PubMed Web of Science ®Google Scholar
• Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2013;129(1):22-7
   PubMed Web of Science ®Google Scholar
• Viswanathan AN, Lee H, Berkowitz R, et al. A prospective fesibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gyn Oncol 2014;132(1):55-60
   PubMed Web of Science ®Google Scholar
• Wergin MC, Roos M, Inteeworn N, et al. The influence of fractionated radiation therapy on plasma vascular endothelial growth factor (VEGF) concentration in dogs with spontaneous tumors and its impact on outcome. Radiother Oncol 2006;79(2):239-44
   PubMed Web of Science ®Google Scholar
• Gorski DH, Beckett MA, Jaskoviak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59(14):3374-8
   PubMed Web of Science ®Google Scholar
• Lee CG, Heijn M, di Tomaso E, et al. Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60(19):5565-70
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S, et al. Stem-cell like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66(16):7843-8
   PubMed Web of Science ®Google Scholar
• Osterlund P, Soveri LM, Isoniemi H, et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011;104(4):599-604
   PubMed Web of Science ®Google Scholar
• Tahover E, Uziely B, Salah A, et al. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 2013;30(1):327
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20(2):227-30
   PubMed Web of Science ®Google Scholar